AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS

Positive Top-Line Results for Tarlatamab in Small Cell Lung Cancer Positive Top-Line Results for LUMAKRAS® (Sotorasib) Plus Vectibix® (Panitumumab) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Aug. 3, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for…

Click here to view original post